References

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

10.1016/s0140-6736(15)01281-7 · 2016 · External reference

BRAF mutant lung cancer: programmed death ligand 1 expression, Tumor mutational burden, microsatellite instability status, and response to immune check-point inhibitors

10.1016/j.jtho.2018.04.024 · 2018 · External reference

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

10.1016/s0140-6736(16)32517-x · 2017 · External reference

PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers

10.1093/annonc/mdy334 · 2018 · External reference

Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma

10.1200/jco.2016.67.2477 · 2016 · External reference

Signatures of mutational processes in human cancer

10.1038/nature12477 · 2013 · External reference

Tumor mutation burden as a biomarker in resected non-small-cell lung cancer

10.1200/jco.2018.78.1963 · 2018 · External reference

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the immunotarget registry

10.1093/annonc/mdz167 · 2019 · External reference

BRAF mutant NSCLC and immune checkpoint inhibitors: results from a real-world experience

10.1016/j.jtho.2018.11.036 · 2019 · External reference

Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal

10.1126/scisignal.2004088 · 2013 · External reference

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

10.1038/s41588-018-0312-8 · 2019 · External reference

Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1

10.1186/s40425-018-0492-x · 2019 · External reference